Home > Subject >

Cardiovascular disease

Addressing Residual Cardiovascular Risk

Charles A. Reasner, M.D.
Volume 29, Number 2, pages 30-31

Advanced Lipid Testing

Michael Cobble, M.D., A.A.F.P., F.N.L.A., and Jill Sellers, B.S.Pharm., Pharm.D.
Volume 29, Number 3, pages 22-26

AIM-HIGH Misses Its Target

Charles A. Reasner, M.D.
Volume 30, Number 3, pages 29-30

Ambulatory Blood Pressure Monitoring

Jennifer Beach, Pharm.D., and Kam Capoccia, Pharm.D., B.C.P.S.
Volume 23, Number 4, pages 12-16

An Evidence-Based Approach for Treating Hypertension in Diabetes

Jan N. Basile, M.D.
Volume 22, Number 2, pages 7-10

Anthropometric Measures As Predictors of Cardiometabolic Risk in Clinical Practice

Katia Cristina Portero McLellan, Ph.D., Nutrition, and Lance A. Sloan, M.D., M.Sc., F.A.C.E. Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas
Volume 35, Number 4, pages 8-11

Beyond Glycemic Control

Nandish Thurkal, M.D., Edward Bergen, D.O., Shailesh Nandish, M.D., Mike Lujan, B.S., Rene Oliveros, M.D., F.A.C.C., and Robert Chilton, D.O., F.A.C.C.
Volume 29, Number 1, pages 13-16

Cardiac Autonomic Neuropathy

Raimund I. Herzog, M.D., Deborah Chyun, Ph.D., R.N., F.A.H.A., and Lawrence H. Young, M.D.
Volume 25, Number 1, pages 34-38

Cardiometabolic Risk, Metabolic Syndrome, and Diabetes: Dysmetabolism and Cardiovascular Risk

Devan Shan, Samir Desai, M.D.
Volume 34, Number 1, pages 11-16

Clinical Controversies in Diabetes

Daniel L. Lorber, M.D.
Volume 21, Number 3, pages 22-32

Commentary: Application of the AACE 2017 Lipid Guidelines to Diabetes

Kathleen Wyne, M.D., Ph.D.
Volume 36, Number 3, pages 7-9

Commentary: CV Risk in Diabetes: T1D is not T2DM

Kathleen Wyne, M.D., Ph.D.
Volume 35, Number 5, pages 23-30

Diabetic Autonomic Neuropathy (Part 1)

J. Joseph Prendergast, M.D.
Volume 20, Number 1, pages 7-14

Diabetic Autonomic Neuropathy (Part 2)

J. Joseph Prendergast, M.D.
Volume 20, Number 2, pages 30-36

Diagnosis and Treatment of Diabetic Cardiomyopathy

Harvey L. Katzeff, M.D.
Volume 24, Number 3, pages 6-10

Direct Renin Inhibition

Curtis Triplitt, Pharm.D., C.D.E., and Shay L. Reichert, Pharm.D., B.C.P.S., C.D.E.
Volume 28, Number 1, pages 6-15

Fatty Liver Disease as a Cardiovascular Disease Risk Equivalent

Ahmed T. Mohameed, M.D., Howard P. Monsour, M.D., And Kathleen L. Wyne, M.D., Ph.D.
Volume 33, Number 2, pages 12-17

Glucose-Lowering Studies—Time to Move On

Charles A. Reasner, M.D.
Volume 27, Number 2, pages 35-36

Hypertension and Type 2 Diabetes

Rene Oliveros, M.D., F.A.C.C., Mike Lujan, B.S., and Robert Chilton, D.O., F.A.C.C.
Volume 29, Number 2, pages 11-14

Insulin Resistance and Vascular Dysfunction

Eugenio Cersosimo, M.D.
Volume 27, Number 2, pages 12-16

Interventional Cardiology and the Patient With Type 2 Diabetes

Melanie Sulistio, M.D., Ramavathi Nandyala, M.D., Michael Lujan, B.S., Adrienne S. Zion, Ph.D., and Robert Chilton, D.O., F.A.C.C.
Volume 26, Number 3, pages 6-13

Is Atherosclerosis Different in Patients With Type 2 Diabetes?

Burton E. Sobel, M.D.
Volume 20, Number 2, pages 7-14

Lipid Changes Associated with Diabetes Therapy

John B. Buse, M.D., Ph.D., C.D.E.
Volume 22, Number 1, pages 24-29

Managing Diabetic Dyslipidemia

Peter P. Toth, M.D., Ph.D., F.A.A.F.P., F.N.L.A., F.C.C.P., F.A.H.A., F.A.C.C.
Volume 29, Number 1, pages 18-25

Managing Major Cardiovascular Risk Factors in Patients with Diabetes

Stephen N. Davis, M.D., F.R.C.P., James R. Sowers, M.D., Douglas E. Vaughan, M.D., F.A.C.C., and Donald S. Nelinson, Ph.D.
Volume 23, Number 3, pages 28-35

Mitigating Cardiovascular Risks in Diabetes

Arnaud Bastien, M.D.
Volume 26, Number 4, pages 14-17

Modifying Insulin Resistance to Prevent Stroke

Karla Martinez, M.D., Silvio E. Inzucchi, M.D., Catherine Viscoli, Ph.D., and Walter N. Kernan, M.D.
Volume 26, Number 2, pages 19-23

Obesity, Insulin Resistance, and Cardiovascular Disease

Tracy McLaughlin, M.D., M.S.
Volume 23, Number 3, pages 6-11

Pathophysiology and Complications of Type 2 Diabetes

Derek D. Mafong, M.D., and Robert R. Henry, M.D.
Volume 28, Number 4, pages 13-26

Position Statement: Treatment of Hypertension in Adults with Diabetes

American Diabetes Association
Volume 22, Number 1, pages 14-19

Practical Prevention and Management of Cardiovascular Disease

Cynthia Rodriguez, M.S. A.R.N.P., F.N.P.-B.C., C.L.S.
Volume 29, Number 1, pages 4-12

Preventing Coronary Artery Disease in Type 2 Diabetes

R. Todd Hurst, M.D., and Richard W. Lee, M.D.
Volume 24, Number 1, pages 14-18

Prevention of Cardiovascular Events in Diabetes

Robert J. Chilton, D.O.
Volume 32, Number 1, pages 6–9

Rational Therapy of Dyslipidemia in Patients With Type 2 Diabetes

Charles A. Reasner, M.D.
Volume 26, Number 4, pages 28-33

Risk Factors for Cardiovascular Disease in Children with Diabetes

Jennifer Miller, M.D., and Janet Silverstein, M.D.
Volume 23, Number 2, pages 13-18

Screening for Asymptomatic Coronary Artery Disease in Diabetes

Samuel Engel, M.D.
Volume 24, Number 3, pages 12-17

Should Glucose Control Prevent Cardiovascular Disease in Type 2 Diabetes?

Kathleen Wyne, M.D., Ph.D.
Volume 33, Number 1, pages 15-17

Should We Use Statins to Lower C-reactive Protein?—Lessons From JUPITER and AURORA

Charles A. Reasner, M.D.
Volume 28, Number 2, pages 24-25

Standards of Medical Care—2006 (Part 3)

American Diabetes Association
Volume 25, Number 3, pages 8-22

The ACCORD Trial

ACCORD Study Group
Volume 23, Number 4, pages 6-11

The Bypass Angioplasty Revascularization Investigation in Patients with Type 2 Diabetes (BARI 2D)

Robert L. Frye, M.D., and Saul Genuth, M.D., on behalf of the BARI 2D Investigators
Volume 22, Number 4, pages 24-26

The Role of Aspirin in the Prevention of Cardiovascular Events in Diabetes

Shailesh Nandish, M.D., and Robert Chilton, D.O., F.A.C.C.
Volume 30, Number 1, pages 11-13

Tight Glycemic Control and Cardiovascular Events

Charles A. Reasner, M.D.
Volume 27, Number 3, pages 26-27

Treatment of Low HDL Cholesterol Level—Too Little, Too Late

Charles A. Reasner, M.D.
Volume 28, Number 1, pages 29-31

Understanding the Links Between Insulin Resistance, Diabetes, and Cardiovascular Risk

Melvin R. Hayden, M.D., and Brian S. McGowan, Ph.D.
Volume 24, Number 2, pages 6-14

Use of Bile Acid Sequestrants to Treat Type 2 Diabetes

Charles A. Reasner, M.D.
Volume 28, Number 2, pages 6-15

Vitamin D Deficiency and Diabetes

David S.H. Bell, M.B., F.A.C.E.
Volume 30, Number 4, pages 6-21

What is the Role of Glucose Control in the Prevention of Cardiovascular Disease in Type 2 Diabetes?


Volume 34, Number 2, pages 12-13

Why Is There More Cardiovascular Disease in Diabetes?

Daniel L. Lorber, M.D.
Volume 25, Number 4, pages 10-15